THIS ANNOUNCEMENT AND THE
INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR
DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH
AFRICA, JAPAN, ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OR
ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
LEI: 254900YT8SO8JT2LGD15
Marwyn Acquisition Company
III Limited
(the
"Company")
Interim Financial Statements
for the period ended 31 December 2023
The Company announces the
publication of its Interim Financial Statements for the period
ended 31 December 2023.
The Interim Financial Statements are
also available on the 'Shareholder Documents' page of the Company's
website at www.marwynac3.com.
Enquiries:
Company Secretary
Antoinette Vanderpuije - 020 7004
2700
WH
Ireland - Corporate Broker 020 7220 1666
Harry Ansell
Katy Mitchell
Marwyn
Acquisition Company III Limited
Unaudited
Interim
Condensed
Consolidated Financial Statements for the six months ended 31
December 2023
MANAGEMENT REPORT
We present to shareholders the
unaudited interim condensed consolidated financial statements (the
"Interim Financial
Statements") of Marwyn Acquisition Company III Limited (the
"Company") for the six
months to 31 December 2023, consolidating the results of Marwyn
Acquisition Company III Limited and its subsidiary MAC III (BVI)
Limited (collectively, the "Group" or "MAC").
Strategy
The Company was incorporated on 31
July 2020 and subsequently listed on the Main Market of the London
Stock Exchange on 4 December 2020. The Company has been formed for
the purpose of effecting a merger, share exchange, asset
acquisition, share or debt purchase, reorganisation, or similar
business combination with one or more businesses. The Company's
objective is to generate attractive long term returns for
shareholders and to enhance value by supporting sustainable growth,
acquisitions, and performance improvements within the acquired
companies.
While a broad range of sectors will
be considered by the Directors, those which they believe will
provide the greatest opportunity and which the Company will
initially focus on include:
• Automotive &
Transport;
• Clean Technology;
• Consumer & Luxury
Goods;
• Banking & FinTech;
• Insurance, Reinsurance &
InsurTech & Other Vertical Marketplaces;
• Media &
Entertainment;
• Healthcare & Diagnostics;
and
• Business-to-Business
Services.
The Directors may consider other
sectors if they believe such sectors present a suitable opportunity
for the Company.
The Company will seek to identify
situations where a combination of management expertise, improving
operating performance, freeing up cashflow for investment, and
implementation of a focussed buy and build strategy can unlock
growth in their core markets and often into new territories and
adjacent sectors.
Activity
During the period, the Directors
have noted a marked increase in the volume of inbound opportunities
and introductions to potential management partners, a number of
whom the Company has engaged in discussions with. The Directors
believe that in the current constrained financing environment, a
listed cash shell becomes an increasingly attractive vehicle for
industry-leading management partners to execute buy and build
strategies.
Results
The Group's profit after taxation
for the period to 31 December 2023 was £237,150 (31 December 2022:
loss of £509,128). The Group held a cash
balance at the period end of £10,032,534 (as at 30 June 2023:
£10,079,604). The Group has not yet acquired an operating business
and as such is not yet generating income from trading
activities.
Directors
The Directors of the Company have
served as directors during the period and until the date of this
report as set out below:
James Corsellis
(Chairman)
Antoinette Vanderpuije
Tom Basset
Dividend Policy
The Company has not yet acquired a
trading business and it is therefore inappropriate to make a
forecast of the likelihood of any future dividends. The Directors
intend to determine the Company's dividend policy following
completion of an acquisition and, in any event, will only commence
the payment of dividends when it becomes commercially prudent to do
so.
Corporate Governance
As a company with a Standard
Listing, the Company is not required to comply with the provisions
of the UK Corporate Governance Code and given the size and nature
of the Group the Directors have decided not to adopt the UK
Corporate Governance Code. Nevertheless, the Board is committed to
maintaining high standards of corporate governance and will
consider whether to voluntarily adopt and comply with the UK
Corporate Governance Code as part of any Business Acquisition,
taking into account the Company's size and status at that
time.
The Company currently complies with
the following principles of the UK Corporate Governance
Code:
· The
Company is led by an effective and entrepreneurial Board, whose
role is to promote the long term sustainable success of the
Company, generating value for shareholders and contributing to
wider society;
· The
Board ensures that it has the policies, processes, information,
time and resources it needs in order to function effectively and
efficiently; and
· The
Board ensures that the necessary resources are in place for the
company to meet its objectives and measure performance against
them.
Given the size and nature of the
Company, the Board has not established any committees and intends
to make decisions as a whole. If the need should arise in the
future, for example following any acquisition, the Board may set up
committees and may decide to adopt the UK Corporate
Governance Code.
Risks
The Company's Audited Annual Report
and Consolidated Financial Statements for the year ended 30 June
2023, which are available on the Company's website, set out the
risk management and internal control systems for the Group and
identifies the risks that the Directors consider to be most
relevant to the Company based on its current status. The Directors
are of the opinion that there have been no changes to the risks
faced by the Company since the publication of the Annual Report and
Consolidated Financial Statements and that these remain applicable
for the remaining six months of the year.
Outlook
The Directors continue to progress
discussions with a number of potential management partners and
investment opportunities across a range of sectors. As a listed
cash shell, with the flexibility of the MAC structure, the
Directors believe the Company is well-positioned to execute a buy
and build strategy, once the management partner has been appointed
and the investment hypothesis narrowed to a specific sectoral
opportunity. The Directors look forward to updating shareholders in
due course.
Each of the Directors confirms that,
to the best of their knowledge:
(a) these Interim Financial
Statements, which have been prepared in accordance with IAS 34
"Interim Financial
Reporting" as adopted by the European Union, give a true and
fair view of the assets, liabilities, financial position and profit
or loss of the Company; and
(b) these Interim Financial
Statements comply with the requirements of DTR 4.2.
Neither the Company nor the
Directors accept any liability to any person in relation to the
interim financial report except to the extent that such liability
could arise under applicable law.
Details on the Company's Board of
Directors can be found on the Company website at
www.marwynac3.com.
James Corsellis
Chairman
27
March 2024
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE
INCOME
|
|
Six months
ended
|
|
Six months
ended
|
|
|
31 December
|
|
31 December
|
|
|
2023
|
|
2022
|
|
Note
|
Unaudited
|
|
Unaudited
|
|
|
£'s
|
|
£'s
|
|
|
|
|
|
Administrative expenses
|
6
|
(271,560)
|
|
(358,238)
|
Total operating loss
|
|
(271,560)
|
|
(358,238)
|
|
|
|
|
|
Finance income
|
|
254,710
|
|
103,110
|
Movement in fair value of
warrants
|
13
|
254,000
|
|
(254,000)
|
Profit / (loss) for the period before tax
|
|
237,150
|
|
(509,128)
|
|
|
|
|
|
Income tax
|
7
|
-
|
|
-
|
Profit / (loss) for the period
|
|
237,150
|
|
(509,128)
|
Total other comprehensive
income
|
|
-
|
|
-
|
Total comprehensive profit / (loss) for the
period
|
|
237,150
|
|
(509,128)
|
|
|
|
|
|
Profit / (loss) per ordinary share
|
|
|
|
|
Basic
|
8
|
0.0187
|
|
(0.0401)
|
Diluted
|
8
|
(0.0011)
|
|
(0.0401)
|
The Group's activities derive from
continuing operations.
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL
POSITION
|
|
As at
31 December
2023
|
|
As at
30 June
2023
|
|
Note
|
Unaudited
|
|
Audited
|
|
|
£'s
|
|
£'s
|
Assets
|
|
|
|
|
Current assets
|
|
|
|
|
Other receivables
|
10
|
23,781
|
|
20,780
|
Cash and cash equivalents
|
11
|
10,032,534
|
|
10,079,604
|
Total current assets
|
|
10,056,315
|
|
10,100,384
|
|
|
|
|
|
Total assets
|
|
10,056,315
|
|
10,100,384
|
|
|
|
|
|
Equity and liabilities
|
|
|
|
|
Equity
|
|
|
|
|
Ordinary Shares
|
14
|
326,700
|
|
326,700
|
A Shares
|
14
|
10,320,000
|
|
10,320,000
|
Sponsor share
|
14
|
1
|
|
1
|
Share-based payment
reserve
|
15,
17
|
169,960
|
|
169,960
|
Accumulated losses
|
15
|
(2,988,075)
|
|
(3,225,225)
|
Total equity
|
|
7,828,586
|
|
7,591,436
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
Trade and other payables
|
12
|
68,729
|
|
95,948
|
Warrants
|
13
|
2,159,000
|
|
2,413,000
|
Total liabilities
|
|
2,227,729
|
|
2,508,948
|
|
|
|
|
|
Total equity and liabilities
|
|
10,056,315
|
|
10,100,384
|
The Interim Financial Statements
were approved by the Board of Directors on 27 March 2024 and were
signed on its behalf by:
James Corsellis
Chairman
|
Antoinette Vanderpuije
Director
|
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN
EQUITY
|
Ordinary
shares
|
|
A
Shares
|
|
Sponsor
share
|
|
Share
based
payment
reserve
|
|
Accumulated
losses
|
|
Total
equity
|
|
£'s
|
|
£'s
|
|
£'s
|
|
£'s
|
|
£'s
|
|
£'s
|
Balance as at 1 July 2022
|
326,700
|
|
10,320,000
|
|
1
|
|
169,960
|
|
(1,773,103)
|
|
9,043,558
|
Total comprehensive loss for the
period
|
-
|
|
-
|
|
-
|
|
-
|
|
(509,128)
|
|
(509,128)
|
Balance as at 31 December 2022
|
326,700
|
|
10,320,000
|
|
1
|
|
169,960
|
|
(2,282,231)
|
|
8,534,430
|
|
Ordinary
shares
|
|
A
Shares
|
|
Sponsor
share
|
|
Share
based
payment
reserve
|
|
Accumulated
losses
|
|
Total
equity
|
|
£'s
|
|
£'s
|
|
£'s
|
|
£'s
|
|
£'s
|
|
£'s
|
Balance as at 1 July 2023
|
326,700
|
|
10,320,000
|
|
1
|
|
169,960
|
|
(3,225,225)
|
|
7,591,436
|
Total comprehensive profit for the
period
|
-
|
|
-
|
|
-
|
|
-
|
|
237,150
|
|
237,150
|
Balance as at 31 December 2023
|
326,700
|
|
10,320,000
|
|
1
|
|
169,960
|
|
(2,988,075)
|
|
7,828,586
|
CONDENSED CONSOLIDATED STATEMENT OF CASH
FLOWS
|
|
Six months
ended
31 December
2023
|
|
Six months
ended
31 December
2022
|
|
Note
|
Unaudited
|
|
Unaudited
|
|
|
£'s
|
|
£'s
|
|
|
|
|
|
Operating activities
|
|
|
|
|
Profit / (loss) for the
period
|
|
237,150
|
|
(509,128)
|
|
|
|
|
|
Adjustments to reconcile total operating profit / (loss) to
net cash flows:
|
|
|
|
|
Finance income
|
|
(254,710)
|
|
(103,110)
|
Fair Value (gain) / loss on warrant
liability
|
13
|
(254,000)
|
|
254,000
|
Working capital adjustments:
|
|
|
|
|
Increase in trade and other
receivables and prepayments
|
10
|
(3,001)
|
|
(9,257)
|
Decrease in trade and other
payables
|
12
|
(27,219)
|
|
(38,532)
|
Net
cash flows used in operating activities
|
|
(301,780)
|
|
(406,027)
|
|
|
|
|
|
Investing activities
|
|
|
|
|
Interest received
|
|
254,710
|
|
103,110
|
Net
cash flows used in investing activities
|
|
254,710
|
|
103,110
|
|
|
|
|
|
Net decrease in cash and cash
equivalents
|
|
(47,070)
|
|
(302,917)
|
Cash and cash equivalents at the
beginning of the period
|
|
10,079,604
|
|
10,483,374
|
Cash and cash equivalents at the end of the
period
|
11
|
10,032,534
|
|
10,180,457
|
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
1. GENERAL INFORMATION
Marwyn Acquisition Company III
Limited was incorporated on 31 July 2020 in the British Virgin
Islands ("BVI") as a BVI
business company (registered number 2040967) under the BVI Business
Company Act, 2004. The Company was listed on the Main Market of the
London Stock Exchange on 4 December 2020 and has its registered
address at Commerce House, Wickhams Cay 1, P.O. Box 3140, Road
Town, Tortola, VG1110, British Virgin
Islands and UK establishment (BR022832) at 11 Buckingham Street,
London WC2N 6DF.
The Company has been formed for the
purpose of effecting a merger, share exchange, asset acquisition,
share or debt purchase, reorganisation or similar business
combination with one or more businesses. The Company has one wholly
owned subsidiary, MAC III (BVI) Limited (together with the Company
the "Group").
2. ACCOUNTING POLICIES
(a) Basis of preparation
These Condensed Consolidated
Financial Statements ("Interim
Financial Statements") have been prepared in accordance with
the IAS 34 Interim Financial Reporting and are presented on a
condensed basis.
The Interim Financial Statements do
not include all the information and disclosures required in the
Annual Financial Statements and should be read in conjunction with
the Group's Annual Report and Financial Statements for the year
ended 30 June 2023 (the "2023
Annual Report"), which is available on the Company's
website, www.marwynac3.com.
Accounting policies applicable to these Interim Financial
Statements are consistent with those applied in 2023 Annual
Report.
(b) Going concern
The Interim Financial Statements
have been prepared on a going concern basis, which assumes that the
Group will continue to be able to meet its liabilities as they fall
due within twelve months from the date of approval. The Directors
have considered the financial position of the Group and have
reviewed forecasts and budgets for a period of at least 12 months
following the approval of the Interim Financial
Statements.
At 31 December 2023 the Group has
net assets of £7,828,586 (30 June 2023: £7,591,436), net assets
excluding warrant liabilities of £9,987,586 (30 June 2023:
£10,004,436) and a cash balance of £10,032,534 (30 June 2023:
£10,079,604). The Company has sufficient resources to continue to
pursue its investment strategy which may include effecting a
merger, share exchange, asset acquisition, share or debt purchase,
reorganisation or similar business combination with one or more
businesses.
Subject to the structure of any
acquisition, the Company may need to raise additional funds to
finance the acquisition in the form of equity and/or debt. The
capital structure of the Company enables it to issue different
types of shares in order to raise equity to fund an acquisition.
The ability of the Company to raise additional funds in relation to
an acquisition may affect its ability to complete that acquisition.
Other factors outside of the Company's control may also impact on
the Company's ability to complete that acquisition. The key risks
relating to the Company's ability to execute its stated strategy
are set out in its 2023 Annual Report, which is available on the
Company's website.
The Company entered into a forward
purchase agreement ("FPA")
on 27 November 2020 with Marwyn Value Investors II LP
(''MVI II LP'') of up to
£20 million, which may be drawn for general working capital
purposes and to fund due diligence costs. Any drawdown is subject
to the prior approval of MVI II LP and the satisfaction of
conditions precedent. At 31 December 2023 £12 million had been
drawn down under the FPA.
Whilst the FPA provides a mechanism
for the Company to raise additional funds, as any drawdown is not
under the exclusive control on the Company, all cashflow and
working capital forecasts have been prepared without any further
draw down on the FPA being assumed.
The Directors have considered
macroeconomic backdrop and the ongoing operating costs expected to
be incurred by the business over at least the next 12 months. Based
on their review the Directors have concluded that there are no
material uncertainties relating to going concern of the Group and
as such the Interim Financial Statements have been prepared on a
going concern basis, which assumes that the Group will continue to
be able to meet its liabilities as they fall due within the next 12
months from the date of approval of the Interim Financial
Statements.
(c) New standards and amendments to
International Financial Reporting Standards
New standards and amendments to International Reporting
Standards
The International Financial
Reporting Standards ("IFRS") applicable to the Interim
Financial Statements of the Group for the six-month period to 31
December 2023 have been applied.
Standards issued but not yet effective
The following standards are issued
but not yet effective. The Group intends to adopt these standards,
if applicable, when they become effective. It is not expected that
these standards will have a material impact on the
Group.
Standard
|
Effective
date
|
Supplier Finance Arrangements
(Amendments to IAS 7 and IFRS 7*);
|
1 January
2024
|
Non-current Liabilities with
Covenants (Amendments to IAS 1);
|
1 January
2024
|
Amendments to IFSR 16 - Lease
liability in sale and leaseback;
|
1 January
2024
|
Amendments to IAS 1 Presentation of
Financial Statements: Classification of Liabilities as Current or
Non-current*; and
|
1 January
2024
|
Amendments to IAS 21 Lack of
Exchangeability.
|
1 January
2025
|
*Subject to EU
endorsement
|
|
3. CRITICAL ACCOUNTING
JUDGEMENTS AND ESTIMATES
The preparation of the Group's
Interim Financial Statements under IFRS requires the Directors to
make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and
liabilities. Estimates and judgements are continually evaluated and
are based on historical experience and other factors including
expectations of future events that are believed to be reasonable
under the circumstances. Actual results may differ from these
estimates.
Significant estimates and
accounting judgements
Valuation of
warrants
The Company, has issued matching
warrants for both its issues of ordinary shares and A shares. For
every share subscribed for, each investor was also granted a
warrant ("Warrant") to
acquire a further share at an exercise price of £1.00 per share
(subject to a downward adjustment under certain conditions).
Previously, the Warrants were exercisable at any time until five
years after the issue date; effective 29 April 2022, the exercise
date for the Warrants was extended to the 5th anniversary of a
Business Acquisition, as defined in Note 13.
The Warrants are valued using the
Black-Scholes option pricing methodology which considers the
exercise price, expected volatility, risk free rate, expected
dividends, and expected term of the Warrants.
4. SEGMENT
INFORMATION
The Board of Directors is the
Group's chief operating decision-maker. As the Group has not yet
acquired an operating business, the Board of Directors considers
the Group as a whole for the purposes of assessing performance and
allocating resources, and therefore the Group has one reportable
operating segment.
5. EMPLOYEES AND
DIRECTORS
The Group does not have any
employees. During the six months ended 31 December 2023, the
Company had three serving Directors: James Corsellis, Antoinette
Vanderpuije, and Tom Basset, no Director received remuneration or
fees under the terms of their director service
agreements.
James Corsellis, Antoinette
Vanderpuije, and Tom Basset have a beneficial interest in the
incentive shares issued by the Company's subsidiary as detailed in
Note 17.
6. ADMINISTRATIVE
EXPENSES
|
For six
months
ended 31
December
2023
|
|
For six
months
ended 31
December
2022
|
|
Unaudited
|
|
Unaudited
|
|
£'s
|
|
£'s
|
Group expenses by nature
|
|
|
|
Professional support
|
258,879
|
|
267,791
|
Non-recurring project, professional
and due diligence costs
|
-
|
|
74,943
|
Audit Fees
|
11,647
|
|
9,750
|
Other expenses
|
1,034
|
|
5,754
|
|
271,560
|
|
358,238
|
7. TAXATION
|
For six
months
ended 31
December
2023
|
|
For six
months
ended 31
December
2022
|
|
Unaudited
|
|
Unaudited
|
|
£'s
|
|
£'s
|
Analysis of tax in period
|
|
|
|
Current tax on profits for the
period
|
-
|
|
-
|
Total current tax
|
-
|
|
-
|
Reconciliation of effective rate and tax
charge:
|
For six
months
ended 31
December
2023
|
|
For six
months
ended 31
December
2022
|
|
Unaudited
|
|
Unaudited
|
|
£'s
|
|
£'s
|
Profit / (loss) on ordinary
activities before tax
|
237,150
|
|
(509,128)
|
Expenses not deductible for tax
purposes
|
(252,922)
|
|
696,064
|
(Loss)/ profit on ordinary
activities subject to corporation tax
|
(15,772)
|
|
186,936
|
(Loss)/ profit on ordinary
activities multiplied by the rate of corporation tax in the UK of
25% (2022: 19%)
|
(3,943)
|
|
35,518
|
Effects of:
|
|
|
|
(Loss)/ profit carried forward for
which no deferred tax recognised
|
3,943
|
|
(35,518)
|
Total taxation charge
|
-
|
|
-
|
The Group is tax resident in the UK.
As at 31 December 2023, cumulative tax losses available to carry
forward against future trading profits were £1,249,554 subject to
agreement with HM Revenue & Customs. There is currently no
certainty as to future profits and no deferred tax asset is
recognised in relation to these carried forward losses. Under UK
Law, there is no expiry for the use of tax losses.
8. LOSS PER ORDINARY
SHARE
Basic earnings per share
("EPS") is calculated by dividing
the profit attributable to equity holders of the company by the
combined weighted average number of ordinary shares
and A shares in issue during the period. Diluted EPS is
calculated by adjusting the combined weighted average number of
ordinary shares and A shares outstanding to assume conversion of
all instruments that are potentially dilutive to the ordinary
shares and A shares.
As the Company has made a profit in
the period 31 December 2023, the Warrants are considered
potentially dilutive. Details on the Warrants in issue are given in
Note 13. In the prior year, due to the Company making a loss, the
potential exercise of the Warrants has had an antidilutive impact
on EPS, resulting in both basic and diluted EPS being the same in
the prior year.
The Company has also issued
Incentive Shares as detailed in Note 17, which may, in the future,
also be dilutive to the ordinary and A shareholders. The Incentive
Shares have not been included in the calculation of diluted EPS in
the current period as per IAS 33, they should be treated as
outstanding until the date from which all necessary vesting
conditions are satisfied. Incentive shares to not become
exercisable until 3 to 7 years post completion of the platform
acquisition (unless certain other events have occurred as detailed
in Note 17) and therefore, as the Company has yet to complete its
platform acquisition, the Incentive Shares are not currently
dilutive.
The Company maintains different
share classes, of which ordinary shares, A shares and sponsor
shares were in issue in the current and prior period. The key
difference between ordinary shares and A shares is that the
ordinary shares are traded with voting rights attached. The
ordinary share and A share classes both have equal rights to the
residual net assets of the Company, which enables them to be
considered collectively as one class per the provisions of IAS 33.
The sponsor share has no distribution rights so has been ignored
for the purposes of IAS 33.
|
For six
months
ended 31 December
2023
|
|
For six
months
ended 31 December
2022
|
|
Unaudited
|
|
Unaudited
|
Basic
|
|
|
|
Profit / (loss) attributable to
owners of the parent (£'s)
|
237,150
|
|
(509,128)
|
Weighted average shares in
issue
|
12,700,000
|
|
12,700,000
|
Basic profit / (loss) per ordinary share
(£'s)
|
0.0187
|
|
(0.0401)
|
|
|
|
|
Diluted
|
|
|
|
Profit / (loss) attributable to
owners of the parent (£'s)
|
237,150
|
|
(509,128)
|
Effect of warrants in
issue
|
(254,000)
|
|
-
|
Adjusted loss attributable to owners
of the parent (£'s)
|
(16,850)
|
|
(509,128)
|
Weighted average shares in
issue
|
12,700,000
|
|
12,700,000
|
Adjustment to number of shares for
warrants
|
2,159,000
|
|
-
|
Adjusted weighted average shares in
issue
|
14,859,000
|
|
12,700,000
|
Diluted loss per ordinary share (£'s)
|
(0.0011)
|
|
(0.0401)
|
The adjustment to earnings of
£254,000 is required under IAS 33 for the purposes of the
calculating the diluted EPS as these are required to be calculated
as being converted at the start of the year, resulting the no fair
value gain. The adjusted weighted average shares adjustment arises
from the treasury share method using a fair value of £0.83 per
share for 12,000,000 warrants over A shares and 700,00 warrants
over ordinary shares respectively, as these warrants are fully
vested and represent potential ordinary shares. Please refer to
Note 13 for further information on warrants in issue.
9. SUBSIDIARY
Marwyn Acquisition Company III
Limited is the parent company of the Group, the Group comprises of
the Company and the following subsidiary as at 31 December
2023:
Company name
|
Nature of business
|
Country of incorporation
|
Proportion of ordinary shares held directly by
parent
|
MAC III (BVI) Limited
|
Incentive vehicle
|
British Virgin Islands
|
100%
|
The share capital of MAC III (BVI)
Limited (the "Subsidiary")
consists of both ordinary shares and Incentive Shares. The
Incentive Shares are non-voting and disclosed in more detail in
Note 17.
There are no restrictions on the
Company's ability to access or use the assets and settle the
liabilities of the Company's subsidiary. The registered
office of MAC III (BVI) Limited is Commerce House, Wickhams Cay 1,
P.O. Box 3140, Road Town, Tortola, VG1110, British Virgin Islands
and its UK Establishment address is 11 Buckingham Street, London,
WC2N 6DF.
10. OTHER
RECEIVABLES
|
As at
31 December
2023
|
|
As at
30 June
2023
|
|
Unaudited
|
|
Audited
|
|
£'s
|
|
£'s
|
Amounts receivable in one year:
|
|
|
|
Prepayments
|
18,420
|
|
14,372
|
Due from a related party (Note
18)
|
1
|
|
1
|
VAT receivable
|
5,360
|
|
6,407
|
|
23,781
|
|
20,780
|
There is no material difference
between the book value and the fair value of the receivables.
Receivables are considered to be past due once they have passed
their contracted due date. Other receivables are all
current.
11. CASH AND CASH
EQUIVALENTS
|
As at
31 December
2023
|
|
As at
30 June
2023
|
|
Unaudited
|
|
Audited
|
|
£'s
|
|
£'s
|
Cash and cash equivalents
|
|
|
|
Cash at bank
|
10,032,534
|
|
10,079,604
|
|
10,032,534
|
|
10,079,604
|
Credit risk is managed on a group
basis. Credit risk arises from cash and cash equivalents and
deposits with banks and financial institutions. For banks and
financial institutions, only independently rated parties with a
minimum short-term credit rating of P-1, as issued by Moody's, are
accepted.
12. TRADE AND OTHER
PAYABLES
|
As at
31 December
2023
|
|
As at
30 June
2023
|
|
Unaudited
|
|
Audited
|
|
£'s
|
|
£'s
|
Amounts falling due within one year:
|
|
|
|
Trade payables
|
3,162
|
|
6,054
|
Due to a related party (Note
18)
|
29,451
|
|
28,656
|
Accruals
|
36,116
|
|
61,238
|
|
68,729
|
|
95,948
|
There is no material difference
between the book value and the fair value of the trade and other
payables. All trade payables are non-interest bearing and are
usually paid within 30 days.
13. WARRANT
LIABLITY
|
Amounts
falling
due within
one
year
|
|
£'s
|
|
|
Fair value of warrants at 30 June 2022
|
2,032,000
|
Fair value movement of warrants:
|
|
Warrant liability - ordinary warrants
|
14,000
|
Warrant liability - A warrants
|
240,000
|
Total fair value movement
|
254,000
|
Fair value of warrants at 31 December 2022
|
2,286,000
|
Fair value movement of warrants:
|
|
Warrant liability - ordinary
warrants
|
7,000
|
Warrant liability - A
warrants
|
120,000
|
Total fair value movement
|
127,000
|
Fair value of warrants at 30 June 2023
|
2,413,000
|
Fair value movement of warrants:
|
|
Warrant liability - ordinary
warrants
|
(14,000)
|
Warrant liability - A
warrants
|
(240,000)
|
Total fair value movement
|
(254,000)
|
Fair value of warrants at 31 December 2023
|
2,159,000
|
On 4 December 2020, the Company
issued 700,000 ordinary shares and matching warrants at a price of
£1 for one ordinary share and matching warrant. Under the terms of
the warrant instrument ("Warrant
Instrument"), warrant holders are able to acquire one
ordinary share per warrant at a price of £1 per ordinary share,
subject to a downward price adjustment depending on
the price of future shares issued prior to or in
conjunction with an initial acquisition.
Warrants are fully vested at the period end.
On 20 April 2021, the Company issued
12,000,000 A shares and matching warrants at a price of £1 for one
A share and matching A warrant. Under the
terms of the A warrant instrument ("A Warrant Instrument"), warrant holders
are able to acquire one ordinary share per warrant at a price of £1
per ordinary share, subject to a downward price adjustment
depending on the price of future shares issued prior to or in
conjunction with an initial acquisition. Warrants are fully vested at the period end.
Effective 29 April 2022, both the
Warrant Instrument and A Warrant Instrument were amended such that
the long stop date was extended to the fifth anniversary of an
initial acquisition by a member of the Group (which may be in the
form of a merger, share exchange, asset acquisition, share or debt
purchase, reorganisation or similar transaction) of a business
("Business Acquisition").
Previously the warrants were exercisable for 5 years from the date
of issue.
Warrants are accounted for as a
level 3 derivative liability instruments and are measured at fair
value at grant date and revalued at each subsequent balance sheet
date. The warrants and A warrants were separately valued at
the date of grant. For both the warrants and A warrants, the
combined market value of one share and one Warrant was considered
to be £1, in line with the price paid by investors. A Black-Scholes
option pricing methodology was used to determine the fair value,
which considered the exercise prices, expected volatility, risk
free rate, expected dividends and expected term.
On 31 December 2023, the fair value
was assessed as 17p per warrant, the result of which is a fair
value gain £254,000 (31 December 2022: loss of £254,000). The
Directors are responsible for determining the fair value of the
warrants at each reporting date, the underlying calculations are
prepared by Deloitte LLP.
The key assumptions used in
determining the fair value of the Warrants are as
follows:
|
As at
31 December
2023
|
|
As at
30 June
2023
|
|
Unaudited
|
|
Audited
|
Combined price of a share and
warrant
|
£1
|
|
£1
|
Exercise price
|
£1
|
|
£1
|
Expected volatility
|
25.0%
|
|
25.0%
|
Risk free rate
|
3.30%
|
|
4.70%
|
Expected dividends
|
0.0%
|
|
0.0%
|
Expected term
|
5th anniversary of the completion of a Business
Acquisition
|
|
5th
anniversary of the completion of a Business Acquisition
|
14. STATED
CAPITAL
Authorised
|
|
|
|
Unlimited ordinary shares of no par
value
|
|
|
|
Unlimited A shares of no par
value
|
|
|
|
100 sponsor shares of no par
value
|
|
|
|
|
|
|
|
|
As at
31 December
2023
|
|
As at
30 June
2023
|
|
Unaudited
|
|
Audited
|
|
£'s
|
|
£'s
|
Issued
|
|
|
|
700,000 ordinary shares of no par
value
|
326,700
|
|
326,700
|
12,000,000 A shares of no par
value
|
10,320,000
|
|
10,320,000
|
1 sponsor share of no par
value
|
1
|
|
1
|
|
10,646,701
|
|
10,646,701
|
On incorporation, the Company issued
1 ordinary share of no par value to MVI II Holdings I LP. On 30
September 2020, it was resolved that updated memorandum and
articles ("Updated
M&A") be adopted by the Company and with effect from the
time the Updated M&A be registered with the Registrar of
Corporate Affairs in the British Virgin Islands, the 1 ordinary
share which was in issue by the Company be redesignated as 1
sponsor share of no par value (the "Sponsor Share").
On 4 December 2020, the Company
issued 700,000 ordinary shares and matching warrants at a price of
£1 for one ordinary share and matching warrant. As a result of the
fair value exercise of the warrants, 14p was attributed to the
warrants and therefore each ordinary share was initially valued at
86p per share. Costs of £275,300 directly attributable to this
equity raise were taken against stated capital during the period
ended 30 June 2021.
On 20 April 2021, the Company issued
12,000,000 A shares and matching A warrants at a price of £1 for
one A share and matching A warrant. As a result of the fair value
exercise of the A warrants, 14p was attributed to the A warrants
and therefore each ordinary share was initially valued at 86p per
share. There were no costs directly attributable to the issue of
these shares.
There has been no issue of any share
capital in the six months ending 31 December 2023.
The ordinary shares and A shares are
entitled to receive a share in any distribution paid by the Company
and a right to a share in the distribution of the surplus assets of
the Company on a winding-up. Only ordinary shares have voting
rights attached. The Sponsor Share confers upon the holder no right
to receive notice and attend and vote at any meeting of members, no
right to any distribution paid by the Company and no right to a
share in the distribution of the surplus assets of the Company on a
winding-up. Provided the holder of the Sponsor Share holds directly
or indirectly 5 per cent. or more of the issued and outstanding
shares of the Company (of whatever class other than any Sponsor
Shares), they have the right to appoint one director to the
Board.
The Company must receive the prior
consent of the holder of the Sponsor Share, where the holder of the
Sponsor Share holds directly or indirectly 5 per cent. or more of
the issued and outstanding shares of the Company, in order
to:
•
Issue any further Sponsor Shares;
•
issue any class of shares on a non pre-emptive basis where the
Company would be required to issue such share pre-emptively if it
were incorporated under the UK Companies Act 2006 and acting in
accordance with the Pre-Emption Group's Statement of Principles;
or
•
amend, alter or repeal any existing, or introduce any new
share-based compensation or incentive scheme in respect of the
Group; and
•
take any action that would not be permitted (or would only be
permitted after an affirmative shareholder vote) if the Company
were admitted to the Premium Segment of the Official
List.
The Sponsor Share also confers upon
the holder the right to require that: (i) any purchase of ordinary
shares; or (ii) the Company's ability to amend the Memorandum and
Articles, be subject to a special resolution of members whilst the
Sponsor (or an individual holder of a Sponsor Share) holds directly
or indirectly 5 per cent. or more of the issued and outstanding
shares of the Company (of whatever class other than any Sponsor
Shares) or are a holder of incentive shares.
15. RESERVES
The following describes the nature
and purpose of each reserve within shareholders' equity:
Accumulated
losses
Cumulative losses recognised in the
Consolidated Statement of Comprehensive Income.
Share based payment
reserve
The share based payment reserve is
the cumulative amount recognised in relation to the equity-settled
share based payment scheme as further described in Note
17.
16. FINANCIAL INSTRUMENTS AND
ASSOCIATED RISKS
The Group has the following
categories of financial instruments at the period end:
|
As at
31 December
2023
|
|
As at
30 June
2023
|
|
Unaudited
|
|
Audited
|
|
£'s
|
|
£'s
|
Financial assets measured at amortised cost
|
|
|
|
Cash and cash equivalents (Note
11)
|
10,032,534
|
|
10,079,604
|
Due from related party (Note
18)
|
1
|
|
1
|
|
10,032,535
|
|
10,079,605
|
|
As at
31 December
2023
|
|
As at
30 June
2023
|
|
Unaudited
|
|
Audited
|
|
£'s
|
|
£'s
|
Financial liabilities measured at amortised
cost
|
|
|
|
Trade payables (Note 12)
|
3,162
|
|
6,054
|
Accruals (Note 12)
|
36,116
|
|
61,238
|
Due to a related party (Note
18)
|
29,451
|
|
28,656
|
|
68,729
|
|
95,948
|
|
|
|
|
Financial liabilities measured at fair value through profit
and loss
|
|
|
|
Warrant Liability
|
2,159,000
|
|
2,413,000
|
|
2,159,000
|
|
2,413,000
|
The fair value and book value of the
financial assets and liabilities are materially
equivalent.
The Group's risk management policies
are established to identify and analyse the risks faced by the
Group, to set appropriate risk limits and controls, and to monitor
risks and adherence limits. Risk management policies and systems
are reviewed regularly to reflect changes in market conditions and
the Group's activities.
Treasury activities are managed on a
Group basis under policies and procedures approved and monitored by
the Board. These are designed to reduce the financial risks faced
by the Group which primarily relate to movements in interest rates.
As the Group's assets are predominantly cash and cash equivalents,
market risk and liquidity risk are not currently considered to be
material risks to the Group.
17. SHARE-BASED
PAYMENTS
Management Long Term
Incentive Arrangements
The Group has put in place a
Long-Term Incentive Plan ("LTIP"), to ensure alignment between
Shareholders, and those responsible for delivering the Company's
strategy and to attract and retain the best executive management
talent.
The LTIP will only reward the
participants if shareholder value is created. This ensures
alignment of the interests of management directly with those of
Shareholders. As at the balance sheet date, an executive management
team is not yet in place and as such Marwyn Long Term Incentive LP
("MLTI") (in which James
Corsellis, Antoinette Vanderpuije and Tom Basset are indirectly
beneficially interested) is the only participant in the LTIP. Once
an executive management team is appointed, they will participate in
the LTIP and this will be dilutive to MLTI. Under the LTIP, A
ordinary shares ("Incentive
Shares") are issued by the Subsidiary.
As at the statement of financial
position date, MLTI had subscribed for redeemable A ordinary shares
of £0.01 each in the Subsidiary entitling it to 100 per cent of the
incentive value.
Preferred
Return
The incentive arrangements are
subject to the Company's shareholders achieving a preferred return
of at least 7.5 per cent. per annum on a compounded basis on the
capital they have invested from time to time (with dividends and
returns of capital being treated as a reduction in the amount
invested at the relevant time) (the "Preferred Return").
Incentive
Value
Subject to a number of provisions
detailed below, if the Preferred Return and at least one of the
vesting conditions have been met, the holders of the Incentive
Shares can give notice to redeem their Incentive Shares for
ordinary shares in the Company ("Ordinary Shares") for an aggregate
value equivalent to 20 per cent. of the "Growth", where Growth means the excess
of the total equity value of the Company and other shareholder
returns over and above its aggregate paid up share capital (20 per
cent. of the Growth being the "Incentive Value").
Grant date
The grant date of the Incentive
Shares will be deemed to be the date that such shares are
issued.
Redemption /
Exercise
Unless otherwise determined and
subject to the redemption conditions having been met, the Company
and the holders of the Incentive Shares have the right to exchange
each Incentive Share for Ordinary Shares in the Company, which will
be dilutive to the interests of the holders of Ordinary Shares.
However, if the Company has sufficient cash resources and the
Company so determines, the Incentive Shares may instead be redeemed
for cash. It is currently expected that in the ordinary course
Incentive Shares will be exchanged for Ordinary Shares. However,
the Company retains the right but not the obligation to redeem the
Incentive Shares for cash instead. Circumstances where the Company
may exercise this right include, but are not limited to, where the
Company is not authorised to issue additional Ordinary Shares or on
the winding-up or takeover of the Company.
Any holder of Incentive Shares who
exercises their Incentive Shares prior to other holders is entitled
to their proportion of the Incentive Value to the date that they
exercise but no more. Their proportion is determined by the number
of Incentive Shares they hold relative to the total number of
issued shares of the same class.
Vesting Conditions and
Vesting Period
The Incentive Shares are subject to
certain vesting conditions, at least one of which must be (and
continue to be) satisfied in order for a holder of Incentive Shares
to exercise its redemption right.
The vesting conditions are as
follows:
i. it is later than the
third anniversary of the initial Business Acquisition and earlier
than the seventh anniversary of the Business
Acquisition;
ii. a
sale of all or substantially all of the revenue or net assets of
the business of the Subsidiary in combination with the distribution
of the net proceeds of that sale to the Company and then to its
shareholders;
iii. a sale
of all of the issued ordinary shares of the Subsidiary or a merger
of the Subsidiary in combination with the distribution of the net
proceeds of that sale or merger to the Company's
shareholders;
iv. where by
corporate action or otherwise, the Company effects an in-specie
distribution of all or substantially all of the assets of the Group
to the Company's shareholders;
v.
aggregate cash dividends and cash capital returns to the Company's
Shareholders are greater than or equal to aggregate subscription
proceeds received by the Company;
vi. a
winding up of the Company;
vii. a winding up
of the Subsidiary; or
viii. a sale, merger or
change of control of the Company.
If any of the vesting conditions
described in paragraphs (ii) to (viii) above are satisfied before
the third anniversary of the initial acquisition, the A Shares will
be treated as having vested in full.
Holding of Incentive
Shares
MLTI holds Incentive Shares
entitling them to aggregate to 100 per cent. of the Incentive
Value. Any future management partners or
senior executive management team members receiving Incentive Shares
will be dilutive to the interests of existing holders of Incentive
Shares, however the share of the Growth of the Incentive Shares in
aggregate will not increase.
The following shares were in issue
at 31 December 2023:
|
Nominal Price
|
Issue
price per A ordinary share £'s
|
Number of A ordinary
shares
|
Unrestricted market value at grant date £'s
|
IFRS 2
Fair value £'s
|
Marwyn Long Term Incentive
LP
|
£0.01
|
7.50
|
2,000
|
15,000
|
169,960
|
Valuation of Incentive
Shares
Valuations were performed by
Deloitte LLP using a Monte Carlo model to ascertain the
unrestricted market value and the fair value at grant date. Details
of the valuation methodology and estimates and judgements used in
determining the fair value are noted herewith and were in
accordance with IFRS 2 at grant date.
There are significant estimates and
assumptions used in the valuation of the Incentive Shares.
Management has considered at the grant date, the probability of a
successful first Business Acquisition by the Company and the
potential range of value for the Incentive Shares, based on the
circumstances on the grant date.
The fair value of the Incentive
Shares granted under the scheme was calculated using a Monte Carlo
model with the following inputs:
Issue
date
|
Share
designation at balance sheet date
|
Volatility
|
Risk-free
rate
|
Expected
term* (years)
|
25 November 2020
|
A
Shares
|
25%
|
0.0%
|
7.0
|
*The expected term assumes that the Incentive Shares are
exercised 7 years post acquisition.
The Incentive Shares are subject to
the Preferred Return being achieved, which is a market performance
condition, and as such has been taken into consideration in
determining their fair value. The model incorporates a range of
probabilities for the likelihood of an Business Acquisition being
made of a given size.
Expense related to Incentive
Shares
There are no service conditions
attached to the MLTI shares and as result the fair value at grant
date of £169,960, less the subscription price of £15,000 (a net
amount of £154,960) was expensed to the profit and loss account on
issue, with the total fair value being recorded in the share-based
payment reserve.
18. RELATED
PARTIES
James Corsellis, Antoinette
Vanderpuije and Tom Basset have served as
directors of the Company during the period. Funds managed by Marwyn
Investment Management LLP ("MIMLLP"), of which James Corsellis is a
managing partner and Antoinette Vanderpuije and Tom Basset are both
partners, hold 75 per cent. of the Company's issued ordinary shares
and warrants and 100% of the A shares and A warrants at the period
end date as well as the Sponsor Share. The £1 due for the Sponsor
Share is remains unpaid at the period end (30 June 2023:
unpaid).
James Corsellis, Tom Basset, and Antoinette Vanderpuije
have a beneficial interest in the Incentive Shares through their
indirect interest in Marwyn Long Term Incentive LP which owns 2,000
A ordinary shares in the capital of MAC III (BVI) Limited
which are disclosed in Note 17.
James Corsellis is the managing
partner of Marwyn Capital LLP, and Antoinette Vanderpuije and Tom
Basset are also both partners. Marwyn Capital LLP provides
corporate finance support, company secretarial, administration and
accounting services to the Company. On an ongoing basis a monthly
fee of £25,000 per calendar month charged for the provision of the
corporate finance services and managed services support is charged
on a time spent basis. The total amount charged in the period ended
31 December 2023 by Marwyn Capital LLP for services was
£182,690 (31 December 2022: £191,522) and they had incurred expenses on behalf of the
Company of £21,423 (31 December
2022: £25,753) and of this £29,451 (30 June
2023: £28,656) was outstanding as at the period end.
19. COMMITMENTS AND CONTINGENT
LIABILITIES
There were no commitments or
contingent liabilities outstanding at 31 December 2023 (31 December
2022: £Nil) which would require disclosure or adjustment in these
Interim Financial Statements.
20. POST BALANCE SHEET
EVENTS
There have been no material post
balance sheet events that would require disclosure or adjustment to
these Interim Financial Statements.
ADVISORS
Company Broker
|
BVI
legal advisers to the Company
|
WH Ireland Limited
|
Conyers Dill &
Pearman
|
24 Martin Lane
|
Commerce House
|
London
|
Wickhams Cay 1
|
EC4R 0DR
|
Road Town
|
+44 (0)20 7220 1666
|
VG1110
|
|
Tortola
|
|
British Virgin Islands
|
|
|
Company Secretary
|
Depository
|
Antoinette Vanderpuije
|
Link Market Services Trustees
Limited
|
11 Buckingham Street
|
The Registry
|
London
|
34 Beckenham Road
|
WC2N 6DF
|
Beckenham
|
Email: MAC3@marwyn.com
|
Kent
|
|
BR3 4TU
|
|
|
Registered Agent and Assistant Company
Secretary
|
Registrar
|
Conyers Corporate Services (BVI)
Limited
|
Link Market Services (Guernsey)
Limited
|
Commerce House
|
Mont Crevelt House
|
Wickhams Cay 1
|
Bulwer Avenue
|
Road Town
|
St Sampson
|
VG1110
|
Guernsey
|
Tortola
|
GY2 4LH
|
British Virgin Islands
|
|
|
|
English legal advisers to the Company
|
Independent auditor
|
Travers Smith LLP
|
Baker Tilly Channel Islands
Limited
|
10 Snow Hill
|
First floor, Kensington
Chambers
|
London
|
46-50 Kensington Place
|
EC1A 2AL
|
St Helier
|
|
Jersey
|
|
JE4 0ZE
|
Registered office
|
+44 (0) 1534 755150
|
Commerce House
|
|
Wickhams Cay 1
|
|
Road Town
|
|
VG1110
|
|
Tortola
|
|
British Virgin Islands
|
|